Supernus Pharmaceuticals to Present Financial Results
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a leading biopharmaceutical company, is gearing up to announce its financial and business results for the first quarter of 2025. The announcement is set to take place after the market closes, on a forthcoming Tuesday in May. Investors and interested parties are encouraged to tune in to learn more about the company's progress during this reporting period.
Leadership Engagement in Conference Call
The company will host an insightful conference call helmed by Jack Khattar, President and CEO, along with Tim Dec, Senior Vice President and CFO. This call will take place in the afternoon, and will provide an opportunity for stakeholders to gain valuable insights into the company's financial health and strategic direction.
How to Participate
For those wishing to take part, a pre-registration option will be available. Participants are encouraged to sign up ahead of time to ensure they receive vital call-in information, including a personalized conference code. It is advised to connect at least 15 minutes before the call to ensure ample time for setup.
Accessing the Webcast
In addition to the live conference call, there will be a webcast available, accessible via the Supernus Pharmaceuticals Investor Relations page. This ensures that even those unable to join live can catch up via a replay, which will be available for two months after the call.
Supernus Pharmaceuticals: A Commitment to CNS Treatment
Supernus Pharmaceuticals is at the forefront of developing treatments specifically targeting central nervous system (CNS) diseases. Their extensive portfolio includes effective solutions for conditions such as attention-deficit hyperactivity disorder (ADHD), dyskinesia linked to Parkinson’s disease, epilepsy, migraines, and more. The company remains dedicated to innovation, with ongoing development of novel CNS product candidates aimed at addressing other disorders including anxiety and depression.
Broader Vision for CNS Products
Supernus Pharmaceuticals is not just focused on existing therapies but is also investing in future possibilities. This includes exploring new treatment avenues for a range of CNS issues which could potentially improve millions of lives. The company's commitment to expanding their neuroscience portfolio illustrates their resolve in finding and offering innovative solutions.
Company Contact Details
Stakeholders interested in more information can reach out to the company's leadership directly. Jack A. Khattar, President and CEO, and Timothy C. Dec, Senior Vice President and CFO, are available for inquiries. For investor-specific queries, Peter Vozzo from ICR Healthcare is also an excellent contact option.
Frequently Asked Questions
What is Supernus Pharmaceuticals' focus?
Supernus Pharmaceuticals specializes in developing treatments aimed at central nervous system (CNS) diseases.
When are the Q1 2025 financial results expected to be announced?
The financial results will be announced after the market closes on a Tuesday in May 2025.
Who will host the financial results conference call?
Jack Khattar, the CEO, and Tim Dec, the CFO, will host the call.
Is there a way to join the conference call?
Yes, interested participants can pre-register online to obtain dialing details and should join 15 minutes before the call begins.
Where can a replay of the conference call be accessed?
A replay will be available on the Supernus Pharmaceuticals Investor Relations website for two months following the live call.
